Zimbabwe Launches Innovative HIV Prevention Drug, Lenacapavir
Harare, Zimbabwe – In a significant step towards combating HIV, Zimbabwe has become one of the first countries globally to roll out lenacapavir, a long-acting injectable drug for HIV prevention. The launch, which began on Thursday, February 19, 2026, offers a new option for individuals at high risk of contracting the virus, requiring administration only twice a year.
A Turning Point in HIV Prevention
Lenacapavir has demonstrated near-total protection in clinical studies, leading some health officials to describe it as a potential turning point in HIV prevention strategies, particularly for high-risk groups [Reuters]. The drug is being initially offered free of charge to populations including sex workers, adolescent girls and young women, gay men, and pregnant and breastfeeding women.
Addressing Challenges with Existing Prevention Methods
For individuals like Constance Mukoloka, a 27-year-old sex worker, lenacapavir offers a welcome alternative to daily oral PrEP (pre-exposure prophylaxis) pills. Mukoloka explained that daily pills often created difficulties with clients and were not always taken consistently, increasing risk. She too noted the stigma associated with carrying PrEP pills, as some clients mistakenly believed they were HIV treatment drugs and avoided her services [Washington Post].
Donor Support and Global Collaboration
The rollout of lenacapavir in Zimbabwe is being supported through the United States President’s Emergency Plan for AIDS Relief (PEPFAR), in partnership with the Global Fund [New Zimbabwe]. The United States has pledged support for access to the drug for approximately 271,000 people in Zimbabwe over the next three years. Similar programs are underway in other African nations, including Zambia and Eswatini.
Zimbabwe’s Success in HIV Control
Zimbabwe, along with Eswatini and Zambia, has emerged as a success story in controlling the HIV epidemic, achieving World Health Organization targets for testing, treatment, and viral suppression. However, new infections remain a concern, particularly among adolescent girls and young women, who experience HIV prevalence rates three times higher than their male counterparts in sub-Saharan Africa [Washington Post].
Challenges to Widespread Access
Despite the promise of lenacapavir, challenges remain in ensuring widespread access. The high cost of the drug and the need for robust health systems are significant hurdles. While Gilead Sciences, the drug’s developer, has committed to selling the drug at no profit to low and middle-income countries, concerns remain about the sustainability of donor funding and the capacity of health systems to deliver the injections effectively [Managed Healthcare Executive].
The Importance of Comprehensive Prevention Strategies
Health authorities emphasize that lenacapavir should complement, not replace, existing prevention tools such as condoms, vaginal rings, and shorter-acting injectables. Condoms remain a crucial component of HIV prevention, offering protection against other sexually transmitted infections as well [Washington Post].
Zimbabwe initially expects about 46,000 people across 24 sites to benefit from the lenacapavir rollout, with plans to expand access as more donor-funded doses become available.